Fig. 3

Procoagulant enzyme complexes formation and inhibition assays. a Intrinsic FXa, b extrinsic FXa, and c thrombin production of platelets and MPs from healthy subjects (n = 33), stage I (n = 16), II (n = 47), III (n = 28), or IV (n = 21) colon cancer patients were evaluated. Intrinsic FXa formation was measured in the presence of FIXa, FVIII and thrombin. Extrinsic FXa production was assessed in the presence of FVIIa. Thrombin generation was investigated in the presence of FXa and FVa. d The capacity of lactadherin (128 nM) to block procoagulant enzyme complexes on platelets and MPs from 21 patients stage IV was evaluated. lactadherin decreased activity of the procoagulant enzyme complexes by approximately 80 % in platelets. Data displayed are mean ± SD. *P <0.001. In-Xa: intrisic FXa; Ex-Xa: extrisic FXa; lact: lactadherin